Gefitinib-induced pneumonitis in non-small cell lung cancer: radiological and clinical findings in five patients.

[1]  T. Johkoh,et al.  Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. , 2006, Lung cancer.

[2]  T. Saikai,et al.  Gefitinib‐induced interstitial lung disease showing improvement after cessation: Disassociation of serum markers , 2006, Respirology.

[3]  K. Uematsu,et al.  Gefitinib‐induced lung injury successfully treated with high‐dose corticosteroids , 2006, Respirology.

[4]  K. Penne,et al.  Gefitinib (IressaTM, ZD1839) and Tyrosine Kinase Inhibitors: The Wave of the Future in Cancer Therapy , 2005, Cancer nursing.

[5]  N. Normanno,et al.  New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. , 2005, Anti-cancer drugs.

[6]  M. Narabayashi,et al.  Acute gefitinib-induced pneumonitis , 2004, International Journal of Clinical Oncology.

[7]  S. Kudoh,et al.  Interstitial lung disease associated with drug therapy , 2004, British Journal of Cancer.

[8]  Hiroshi Tanaka,et al.  Acute lung injury as an adverse event of gefitinib , 2004, Anti-cancer drugs.

[9]  G. Giaccone,et al.  Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. , 2003, The oncologist.

[10]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[11]  G. Rabinowits,et al.  Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. , 2003, Anti-cancer drugs.

[12]  T. Goya,et al.  [Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report]. , 2003, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

[13]  I. Okamoto,et al.  Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. , 2003, Lung cancer.

[14]  M. Ebina,et al.  Severe acute interstitial pneumonia and gefitinib , 2003, The Lancet.

[15]  Roy S Herbst,et al.  Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Baselga.  Why the epidermal growth factor receptor? The rationale for cancer therapy. , 2002, The oncologist.

[17]  M. Ranson.  ZD1839 (Iressa): for more than just non-small cell lung cancer. , 2002, The oncologist.

[18]  M. Kris,et al.  ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Prows,et al.  Dose-related protection from nickel-induced lung injury in transgenic mice expressing human transforming growth factor-alpha. , 2002, American journal of respiratory cell and molecular biology.

[20]  F. Khuri,et al.  ZD1839 (Iressa) in non-small-cell lung cancer. , 2002, Clinical lung cancer.

[21]  D. Prows,et al.  Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-α. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[22]  K. O'Hanlon.  New drugs in cancer therapy. , 1998, IDrugs : the investigational drugs journal.

[23]  G. Raghu,et al.  Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. , 1998, American journal of respiratory and critical care medicine.

[24]  D. Madtes,et al.  Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats. , 1994, American journal of respiratory cell and molecular biology.